Tilray Shares Slide as Regulatory News Triggers Profit-Taking

Tilray US88688T1007

Tilray Brands, Inc. saw its stock decline sharply in Friday's trading session, shedding approximately 8.4% of its value. This pullback occurred despite a historic move by the U.S. President to reclassify cannabis, illustrating a classic case of investors selling on the confirmation of anticipated news. The preceding sector rally may have simply run too far, too fast.

On the Nasdaq, shares closed near $11.11, while the Toronto Stock Exchange listing settled around CAD $15.50. The volatility was sparked by the formal confirmation that a directive to move cannabis from Schedule I to Schedule III was signed on December 18, 2025. While this regulatory shift acknowledges medical utility and removes significant tax disadvantages, many market participants used the official announcement as a cue to realize profits. The trading pattern perfectly exemplified the adage "buy the rumor, sell the news."

In immediate response to the regulatory change, the company announced the establishment of "Tilray Medical USA." This new division is designed to accelerate its entry into the U.S. medical cannabis market. CEO Irwin Simon called the presidential order a constructive step but tempered expectations, noting it represents an incremental transition rather than an immediate gateway to full federal legalization of recreational use.

Cautious Analyst Adjustments Amid Decline

Even with the stock's retreat, analysts are updating their models to reflect the new landscape. The research firm Sanford C. Bernstein modestly raised its price target for the Canadian-listed shares to CAD $13.60. However, this revised target still implies potential for further downside from recent opening price levels.

This recent setback must be viewed within the context of the preceding days. Rumors of the impending executive order had propelled Tilray's share price and the broader cannabis sector significantly higher. Key competitors, including Canopy Growth, and the sector ETF MSOS, also posted double-digit percentage corrections on Friday.

From a fundamental perspective, challenges remain for Tilray. The elimination of tax burdens under Section 280E is expected to improve cash flow, but a substantial debt load continues to weigh on the balance sheet. The company had only just completed a 1-for-10 reverse stock split on December 1, 2025, a move executed to maintain exchange compliance and stabilize its share structure.

Navigating the Path Forward

Short-term volatility is likely to persist as the market digests the technical details of the rescheduling process. From a charting perspective, the stock is now testing a support zone around $11.00, which represents a logical consolidation phase following a period where technical indicators like the Relative Strength Index (RSI) suggested overheated conditions.

The long-term outlook hinges critically on the implementation timeline. Market observers speculate that certain CBD-based products could become eligible for Medicare reimbursement as early as April 2026. Such a development would provide a concrete revenue catalyst for the newly formed U.S. medical division.